Life Sciences Today

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kim Boericke, the new CEO at Veristat! In this episode, I sit down with Kim to explore what it really takes to build and lead a durable CRO in a rapidly shifting life sciences landscape. We discuss Kim’s leadership journey, how value is created and captured in services-heavy businesses, and what Veristat is prioritizing for customers over the next 12 months. The conversation then goes deeper into the idea of moats—what makes a CRO genuinely hard to copy, what compounds over time, and how strategic decisions today shape defensibility five years out. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. How do you create value for your customers? How do you capture the value? What are three things you’d like to achieve in the next 12-18 months? What makes a CRO genuinely hard to copy? What compounds over time? How do the strategic decisions you make today shape out defensibility five years from now? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Josh Haimson, Co-Founder and CEO at Inductive Bio! Josh Haimson joins me to talk about how their virtual lab can run millions of in silico experiments to predict how molecules will behave in the body and surface the strongest hypotheses to test in the wet lab. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. How do you create value for your customers? How do you measure the value? What are three things you’d like to achieve in the next 12-18 months? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Olympian-turned-founder Simon Arkell joins Life Sciences Today to explain how Ryght.ai is reinventing clinical trial site selection. He unpacks digital twins for 100,000+ sites, AI agents, and why EMR-centric models are an anti-pattern—showing how sponsors can slash enrollment risk, save hundreds of millions, and scale globally. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. How do you create value for your customers? How do you measure the value? What are three things you’d like to achieve in the next 12-18 months? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Asta Ratkeviciene, Co‑Founder and CEO at MedSyntra. In this episode of Life Sciences Today, I talk with Ratkeviciene about building a global, ethically sourced medical imaging data infrastructure across radiology, pathology, oncology, and women’s healthcare. Ratkeviciene explains how MedSyntra aggregates and de-identifies millions of imaging studies, provides a highly curated data marketplace and platform for institutions that require data sovereignty, and partners with clinical experts for annotation and external teams for model development. They discuss why imaging is the core focus, how population differences can degrade AI performance across geographies, MedSyntra’s evolving business model, and the biggest anti‑patterns Ratkeviciene sees in the medical AI ecosystem today. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: What’s the most important thing people misunderstand about medical imaging data? Who must have this infrastructure before they can deploy serious AI? When did you realize you weren’t building a dataset—but infrastructure? What early decision optimized for long-term trust rather than speed? Where does ethical data sourcing actually slow you down commercially? Have you walked away from data that would have helped the business—but violated your principles? Do you think ethical language is sometimes used to hide poor data practices? Why do imaging AI models quietly fail when they cross borders? When does population bias show up—training or deployment? Why can’t this be solved with more data alone? How do you reconcile local data control with global AI learning? Do we end up with federated intelligence—or fragmented ecosystems? What’s harder: collecting imaging data or producing clinically meaningful labels? If annotation quality doubled, what would that unlock that most people aren’t expecting? What’s the biggest anti-pattern you see in medical AI today? Ten years from now, what will seem obvious about medical imaging AI that people are still ignoring today? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Erez Lampert, Founder and CEO at PathKeeper Surgical! I talk with Lampert about his journey from Israel’s aerospace industry and Invisalign’s Itero scanner to founding PathKeeper in 2018–2019. We dig into the core problem in spine surgery—surgeons “flying blind” between low‑cost, high‑radiation fluoroscopy and ultra‑expensive robotics—and how PathKeeper offers a third way using optical 3D imaging and AI. Erez explains their dual business model (capital + disposables, plus a “razor blade” model via implant partners in a $10B US spine market), and how strategic deals with High Ridge Medical (Zimmer Biomet spine) and Vizient unlock scalable US commercialization without a 50‑person direct sales team. The conversation challenges the myth that Israelis don’t know how to sell in the US, reframing success as understanding gatekeepers, GPOs, and distribution science rather than just raising $50M and hiring a big sales force. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: What problem are spine surgeons facing today, and why is “flying blind” so dangerous? How does PathKeeper’s 3D imaging + AI platform actually work in the OR, and how is it different from fluoroscopy and million‑dollar robots? What is PathKeeper’s business model, and how does the implant “razor blade” model create leverage in a $10B US spine market? How did the High Ridge Medical and Vizient deals come together, and what do they change for commercialization? Why is the common investor advice, “raise $50M and build a huge US sales team’ the wrong playbook here? What are the biggest anti‑patterns in the spine/med‑device industry today? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Kiril Pevsner, Co-Founder and CTO at Protai. We kick this episode off by discussing how Pevsner creates and captures value with pharma. Then we talk about where AI meaningfully shapes decisions in the early discovery and preclinical work. Next, we take a look at where pharma teams hesitate to act on AI-driven insights, even when the science looks strong. We conclude this episode with Pevsner sharing where he doesn’t think AI should be used in drug discovery or development, at least with today’s tools and incentives. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: How do you create and capture value with pharma? From what you see building Protai, where does AI meaningfully shape decisions in early discovery or preclinical work — especially decisions that partners or pharma teams later have to trust? Where do pharma teams hesitate to act on AI-driven insight, even when the science looks strong? Where do you think AI should not be used yet in drug discovery or development, at least with today’s tools and incentives? Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Sagi Sigali, Father and Founder of Rafa’s Moonshot – a non-profit dedicated to Landing a Cure for STXBP1. Sagi and I discuss how Rafa’s Moonshot is turning a rare genetic disorder (STXBP1) into an investable, de‑risked therapeutic opportunity. Sagi explains how his tech/entrepreneur background shapes a for‑profit mindset around fundraising, biopharma partnerships, and making rare disease indications attractive to industry. They cover building a global network, leveraging grants and consortia, working with academia/CROs, and planning the flip from nonprofit to for‑profit. They also dig into industry “anti‑patterns,” including copy‑paste development strategies, and explore a strategy to start from the drug label and work backwards. Sagi closes with his vision for a complete STXBP1 solution, a new CNS neurogenetic research center in Israel, and a stronger Israeli life sciences ecosystem. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: How does Rafa’s Moonshot actually create value for drug and biotech companies working on STXBP1? What does the market and patient landscape look like for STXBP1 as a rare disease? How has your background as a serial tech entrepreneur influenced your strategy in rare disease therapeutics? What are you doing to make STXBP1 attractive enough to enter big‑pharma pipelines? How do conversations with academics, clinicians, CROs, and biopharmas translate into real progress? What is your consortium model, and how do grants and non‑dilutive funding fit into it? How are you using CROs in preclinical work and thinking about IP and cell line development? What do you see as the biggest anti‑pattern in rare disease/drug development today? What are the top three things you want to achieve for STXBP1 patients in the next year? What is your five‑year vision for STXBP1, for Rafa’s Moonshot, and for the Israeli life sciences ecosystem? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Zina Sarif, Founder and CEO at Yendou. Zina Sarif is one of the most dynamic and inspirational founders I’ve met. She grew up in Morocco until age 20 and, after her PhD in biology, spent a decade in cancer drug discovery before leading clinical research at Parexel and PhIII oncology trials at AstraZeneca. Driven by the vision of a cancer-free world, she built Yendou to accelerate research, streamline site operations, and deliver life-saving treatments faster. Yendou streamlines the site selection process and the interaction between CROs, sponsors, and sites, producing 2X improvements in productivity. One of my other guests from Lindus Health said it best, “Everyone is more productive with Yendou. We accelerated feasibility timelines by 50% while reducing manual follow-ups by 70%.” Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell us about your personal journey—how did you get from consulting and Viva to leading Ledger Run? Who are your customers, and what specific problems are you solving for them? How do you create value for sponsors and CROs in clinical trial site selection and relationship management? How do you capture that value—what does your business/revenue model look like? What is the biggest anti–design pattern you see in the industry right now? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is John Chinnici, CEO at Ledger Run. I talk with Chinnici about his journey from consulting (Andersen, IBM) to Viva, where he helped launch and grow Vault, and eventually to leading Ledger Run. Ledger Run focuses on the “unsexy but critical” operational layer of clinical trials: contracting and paying investigative sites. Chinnici explains how delayed, incorrect, and bureaucratic payments have become an accepted but damaging status quo in clinical research, despite sites running on razor-thin margins. Ledger Run’s SaaS platform and services aim to ensure strict contract compliance, dramatically improve operational efficiency, and turn reliable payments into a competitive advantage for sponsors in site recruitment. Chinnici also argues that a major industry anti-pattern is pouring AI investment into volatile early research use cases while underinvesting in high-ROI operational applications such as automating invoice processing and other repetitive payment workflows. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell us about your personal journey—how did you get from consulting and Viva to leading Ledger Run? Who are your customers, and what specific problems are you solving for them? How do you create value for sponsors and CROs in clinical trial payments and contracts? How do you capture that value—what does your business/revenue model look like? What are three things you want to do for your customers in the next 12–18 months to make them insanely happy? What is your competitive moat—what makes Ledger Run hard to copy compared with large CROs and other players? What is the biggest anti–design pattern you see in the industry right now? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Gary Zammit, PhD, President and Chief Executive Officer at Clinilabs. We often imagine medical breakthroughs as the result of data, protocols, and lab science alone. But Gary Zammit has seen firsthand that bringing therapies to patients requires far more: resilient teams, disciplined processes, and cultures that can weather setbacks. In his new book, Beyond the Science: How People, Process, and Systems Transform the Business of Life Sciences, Zammit offers readers an inside look at the real drivers of innovation. From navigating near-bankruptcy at Clinilabs to helping advance more than twenty therapies across thirteen CNS indications, his stories highlight the human and organizational forces that shape the future of medicine. Whether you are in healthcare, business leadership, or organizational strategy, Beyond the Science is both a practical guide and an urgent call to action: to build organizations as resilient and innovative as the science they support because patients are waiting. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. How did that shape you as a leader, and how did those experiences lead you to write Beyond the Science? From your vantage point at Clinilabs, what’s the most misunderstood people-or-process failure in drug development — and how does Clinilabs create value by solving it? How do you prove to sponsors that you’ve actually solved it? CROs often look interchangeable from the outside, yet Clinilabs has built a reputation in one of the most challenging therapeutic areas. Where does your defensibility — your ‘moat’ — really come from? What does Clinilabs do that sponsors or big site networks like Velocity Clinical can’t easily copy? In the closing of the book, you emphasize pushing beyond ‘good enough’ and building teams, systems, and processes that strive for greatness. Looking ahead 12–18 months, what are the three things you want to do for your customers that will raise the bar — things that will materially improve the way CNS trials get run? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guests today are Jamie Luu, RDN, LDN, Strategy and Nutrition Manager, and Ronja Kröger, Nutrition & Product Expert, M. Sc. Nutritional and Food Sciences at Almased. The Almased-type diet can boost natural satiety signals via GLP-1 and PYY — that is real and meaningful. But the new GLP-1-RA drugs go much further: they hijack those same signals, ramp them much higher, and translate into large weight losses in patients with obesity. So the diet is a “natural nudging” of the system; the drugs are a strong “override” of the system. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: You’re showing that the Almased high-protein diet raised GLP-1 and PYY levels — how would you compare that to what we know about the injectable GLP-1 drugs (like Ozempic)? Is the mechanism the same, just a different scale, or is there something qualitatively different going on? I read the IIS paper from 2021 and the results are impressive. Given that the diet intervention was isocaloric (same calories) and short-term, yet still changed appetite-hormone profiles — is Almased complementary to GLP-1 drugs like Ozempics or a preventive/maintenance tool for people who aren’t yet eligible for—or don’t want—drugs? For someone who isn’t on GLP-1 medication, what are realistic expectations of using a high-protein total diet replacement in terms of appetite regulation, hormone effects, and perhaps weight maintenance? And how should they view that in the context of the new drug therapies that dominate headlines? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Denali Rose, VP at Veeva, and Co-Host of Note to File. Rose’s parents are outdoors people and named her after the national park in Alaska. Personally, this is one of the most fun shows we’ve ever done. ‘Nuff said – get in and listen! She is Vice President Sales & Strategy, Site Solutions at Veeva. That’s her day job – she’s also the Co-Host and Producer of the Note To File podcast. She’s focused on delivering solutions for clinical research sites, guiding the sales cycle, and aligning strategy to drive impact and growth. She’s super smart and extremely experienced in the patterns and anti-patterns in the clinical trial industry. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. How did you get into podcasting, and why do you think it’s important? CROs are part of the problem, and therefore, they cannot be a part of the solution; sites will inherit the Earth – what is your take on this? Do you think CROs are part of the problem and therefore can’t be part of the solution? Do you think sites will actually inherit the Earth? What other hats do you wear besides ClinOps? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Daniel Blumenthal, VP of Strategy at MDClone. I talk with MDClone’s VP Strategy about how the company evolved from an early synthetic data pioneer (2016) into a broader data-access and data-extraction platform in a now-crowded market (Snowflake, Oracle, Epic, many synthetic data vendors). Our discussion explores MDClone’s core “nexus” capability of extracting privacy-protected, row-level longitudinal patient data from heterogeneous healthcare systems and producing different types of synthetic data for distinct use cases (research, cross-site collaboration, model development/validation). A major theme is the industry shift from focusing mainly on data access/privacy to treating data integrity and trust as the new frontier and core IP for health systems, pharma, and AI. We debate strategic moats (product vs. project, partnerships vs. competition, where MDClone controls the data supply chain) and how MDClone can remain indispensable as AI and analytics mature. The episode closes with how all this ultimately must translate into better patient outcomes and trustworthy next-generation AI models. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: How has MDClone evolved over the nine years since you became the first employee outside Israel? Synthetic data is now crowded and partially commoditized; what still differentiates MDClone in 2025? In the CIA triad (confidentiality, integrity, availability), is the real new frontier now data integrity rather than access/privacy? What specific part of the healthcare data supply chain does MDClone control that large partners like Snowflake, Epic, or Palantir cannot easily replace? Is MDClone ultimately a product company or a series of bespoke projects, given all the customization and services required? How do you use synthetic data differently for distinct utilities (knowledge gain, cross-site collaboration, model development/validation)? What do you think about trust, privacy, and the patient’s role when patient data is treated as core IP for organizations? How can MDClone help ensure that AI models (including LLMs) are trained and validated on high-integrity, trustworthy data rather than “shitty data”? In a world where every major player can analyze clinical data, what will make MDClone indispensable? How do you see MDClone’s role in directly improving patient outcomes through better data and analytics? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is David Bates, Founder and CEO at Linus Health. I talk with David Bates about Linus Health’s mission to transform brain health from late-stage “sick care” to proactive, preventive care. David explains his journey from signal detection research and investing in built-environment technologies to founding Linus Health around the insight that behavior is the primary observable output of the brain. We discuss Linus’s 3-minute digital cognitive assessments that turn rich behavioral signals into thousands of digital biomarkers, enabling highly sensitive, objective measurement of cognition and early detection of impairment years before symptoms. Our conversation covers the company’s focus on primary care and health systems as core customers, revenue and ROI in fee-for-service and value-based care, and Linus’s data moat of large, diverse, longitudinal datasets. We explore how clinically integrated, consumer-accessible tools could make brain health monitoring continuous—like a “blood pressure cuff for the brain”—and why this paradigm shift is critical for both healthcare delivery and drug development. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: How did your background in signal detection, multimodal sensing, and investing lead you to found Linus Health? What does Linus Health’s platform actually do, and how are your digital assessments different from traditional paper-based cognitive tests? Who are your main customers today (primary care, health systems, pharma, payers), and how do you create and capture value across these different buyer types? How do you translate thousands of digital biomarkers and AI/ML models into clinically meaningful insights, and how often are your models updated? What is your long-term vision? Is the biggest opportunity in supporting drug development, or in becoming a clinically integrated, mass-market “Internet of bodies” brain health platform for consumers? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Philip Poulidis, CEO at Toronto-based ODAIA. Poulidis is tackling one of pharma’s biggest bottlenecks: slow, siloed commercial analytics. Spun out of academic research, ODAIA’s real-time AI platform unifies patient and HCP journey data, replacing months-old reports with dynamic insights that help reps, liaisons, and marketers target the right physicians at the right time — improving prescriptions, outcomes, and patient access. regulated by the USDA/FDA. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. Tell me about ODAIA AI. Who are your customers? How do you create value? How do you capture value from customers? What are three things you want to do for your customers in the next 12-18 months? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Walt Pebley, Chief Scientific Officer at OFD Life Sciences. With over four decades in lyophilization, Walt Pebley has helped OFD become the gold standard in stabilizing probiotics, biologics, and therapeutics. His journey — from personal tragedy to pioneering new delivery platforms — highlights how freeze drying shapes the future of medicine, from shelf-stable powders to novel formats for pain, diabetes, and neurology drugs, food, and dietary supplements regulated by USDA/FDA. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. Tell me about OFD Life Sciences. Who are your customers? How do you create value? How do you capture value from customers? What are three things you want to do for your customers in the next 12-18 months? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Tiffany Callahan, Lead Architect of Agentic AI Systems at SandboxAQ. As a physicist, I love her approach to Large Quantitative Models trained on physics, chemistry, biology, and math to model the real world. Most of the companies in this space are building statistical models by: integrating large datasets for target identification by analyzing genomic and multi-omic data virtual screening to identify promising drug candidates novel molecule design and property prediction (toxicity, efficacy, pharmacokinetics) clinical trial optimization through patient selection and outcome prediction drug repurposing by finding new uses for existing drugs Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. Tell me about SAIR. Who are your customers? How do you create value? How do you capture value from customers? What are three things you want to do for your customers in the next 12-18 months? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Jeff Gombala, Founder and CEO at Evidexa. Jeff Gombala started Helios Innovation with an idea that seems obvious – use expert knowledge and AI models to validate healthtech and medtech products. We’re going to talk about Jeff’s journey, the value they are creating, how they’re turning that into a business, and where they want to take customers by 2026. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: Tell me about your journey. How do you create value for your customers? How do you capture value? What are three things you’d like to achieve for your customers in the next 12 months? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is David Lazerson, Co-Founder and CEO at Briya. Briya started in 2020 with a bold idea — using cryptography and zero-knowledge proofs to make healthcare data shareable, secure, and compliant. Fast forward to today, they’ve just launched Briya AIRE, a clinical-grade AI research platform that promises to let researchers ask questions in plain English and get scientifically robust answers back — without writing code. We’re going to talk about David’s journey, the value Briya is creating, how they’re turning that into a business, and where they want to take customers by 2026. Check out the main topics of discussion for this episode of the Life Sciences Today podcast: What made you start with something as gnarly as zero-knowledge proofs for healthcare data? At what point did you realize infrastructure wasn’t enough, that people wanted insights, not just secure pipes? What customer conversations tipped you off that AI was the next layer? For a researcher using AIRE, what’s the moment when the lightbulb goes on? Which use case best shows the value — the one where you thought, ‘okay, this is working’? How quickly can a researcher go from a question in plain English to a publishable-level output? Validation is one thing — but startups live or die on turning that into repeatable business. What did you have to prove to your Series A investors to show Briya could cross that chasm? I know you probably can’t share exact revenue, but when investors leaned in, what was the strongest signal they saw that Briya wasn’t just another pilot project? Contracts signed, pipeline size, or something else? If we sit down again in 18 months, what would you want to point to as real traction? What’s the one thing you think customers will be most surprised that Briya can do for them by 2026? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!

We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Shai Melcer, Head of the National Program for Bioconvergence at The Israel Innovation Authority. We kick this episode off by first learning what bioconvergence is. Then we talk about who The Israel Innovation Authority’s customers are. Next, we examine why this is such a unique opportunity for Israel. But no opportunity is without its competition, so we talk about how Melcer is competing with cyber and defense — which are huge sectors here. Melcer then also shares how he is competing against big companies like Sandbox AQ. Next, we discuss how The Israel Innovation Authority creates and captures value. Lastly, we conclude this episode with Melcer sharing three things he wants to do for his customers.  Check out the main topics of discussion for this episode of the Life Sciences Today podcast: What is bioconvergence? Who are your customers? Why is this a unique opportunity for Israel? How do you compete with cyber and defense, which are huge sectors here? How do you compete with companies like Sandbox AQ, which spun off from Google quantum computing, raised $950M, and just released the largest publicly available binding affinity dataset with co-folded 3d structures on Hugging Face?  How do you create value? How do you capture value from your customers? What are 3 things you want to do for your customers? Now, without further ado, we’re excited to share with you the next episode of the Life Sciences Today podcast. Subscribe to Danny’s newsletter to get strategic patterns for life science leaders building a defensible business. Be sure to subscribe to the Life Sciences Today Podcast on your favorite podcasting platform: Apple Podcasts Spotify iHeartRadio Amazon Music Pandora YouTube Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on Healthcare IT Today. As a former pharma-tech founder who bootstrapped to exit, I now help TechBio and digital health CEOs grow revenue—by solving the tech, team, and go-to-market problems that stall your progress. If you want a warrior by your side, connect with me on LinkedIn. If you work in Life Sciences IT, we’d love to hear where you agree and/or disagree with our takes on health IT innovation in life sciences. Feel free to share your thoughts and perspectives in the comments of this post, in the YouTube comments, or privately on our Contact Us page. Let us know what you think of the podcast and if you have any ideas for future episodes. Thanks so much for listening!